Oxlumo (Lumasiran Sodium) Patent Expiration, LOE Window & CMS Spending

Oxlumo (Lumasiran Sodium) by Alnylam Pharmaceuticals: FDA Orange Book core substance LOE 2041-05-29, 0 AB generics, $14.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAlnylam Pharmaceuticals
FDA Application & PathwayN214103 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2041-05-29
Last Listed Patent or Exclusivity Date2041-05-29
Orange Book Patents (*PED Extensions)15 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$14.0M
2024 Medicare Part D Spend$6.4M
2024 Medicaid Spend$7.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Alnylam Pharmaceuticals across sibling Meru public-data platforms.